BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.

Exclusion Criteria19

• Previous randomization in the trial
• Any concomitant condition resulting in a life expectancy of less than one month
• Previously diagnosed left ventricular ejection fraction <50%
• Known cardiomyopathy (except previous Takotsubo syndrome)
• Known hemodynamically significant valve disease (moderate or severe aortic/mitral regurgitation) or stenosis
• Heart transplant or left ventricular assist device recipient
• Most recent (within the most recent 3 months) haemoglobin ˂10 g/dL
• Systolic blood pressure <80 mm Hg at screening
• Estimated glomerular filtration rate <30 mL/min/1.73m2
• Current dialysis
• Pregnancy or of childbearing potential who is not sterilized or is not using a medically accepted form of contraception
• Not suitable in the opinion of the investigator due to severe or terminal comorbidity with poor prognosis, or characteristics that may interfere with adherence to the trial protocol
• Any contra-indication for treatment with adenosine or dipyridamole (including AV-block II and III, sick-sinus syndrome in subjects who don´t have a functioning pacemaker, unstable angina, ongoing treatment with dipyridamole)
• Severe asthma (defined as asthma requiring medium or high-dose inhaled corticosteroids combined with other long-acting medications) and severe Chronic Obstructive Pulmonary Disease (COPD), (defined as FEV-1 ˂ 50 %)
• Ongoing treatment with dipyridamole
• Declined participation in study 1
• Any contra-indication for anticoagulant treatment.
• Current indication for treatment with, anticoagulant or dual antiplatelet therapy
• Declined participation in study 2